Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  MDxHealth  /  koers MDxHealth naar 15,25 en later naar 47 euro

Ontvang nu dagelijks onze kooptips!

word abonnee

koers MDxHealth naar 15,25 en later naar 47 euro

1.073 Posts
Pagina: «« 1 ... 20 21 22 23 24 ... 54 »» | Laatste | Omlaag ↓
  2. [verwijderd] 28 juni 2016 08:10
    quote:

    Natte krant schreef op 30 november 2015 17:55:

    Zeg inspirator is het nou niet een wijs idee om deze draad te sluiten...?
    Of wil je wachten op €0?
    MdxHealth is de wereld aan het veroveren.

    Laagste koersdoel van 15,25 euro komt snel dichterbij.

    MDxHealth Secures New Reimbursement Coverage for SelectMDx
    Contract with Fortified Provider Network Covers 5 Million Lives

    IRVINE, CA, and HERSTAL, BELGIUM - June 28, 2016 - MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured reimbursement coverage agreement for its SelectMDx(TM) for Prostate Cancer test with Fortified Provider Network. This agreement serves all 50 states, offering patients greater access to MDxHealth's liquid biopsy test.

    Fortified Provider Network (FPN), is a direct-contracted preferred provider network with 5 million covered lives across the US. Under the agreement, SelectMDx for Prostate Cancer will be made available for members of Fortified's network, which includes self-funded employer groups, insurance carriers and regional and local provider networks that process end-user patient claims.

    "This agreement with FPN will significantly expand coverage for SelectMDx to patients across the United States," said Dr. Jan Groen, Chief Executive Officer of MDxHealth. "This marks another milestone in our commercial strategy for this newly launched test and in our mission to provide the urology community validated and impactful molecular diagnostic solutions, which address unmet medical needs for cancer patients."

    About Fortified Provider Network

    Fortified Provider Network ("FPN") is a national direct-contracted preferred provider network. FPN's select provider network is utilized by self-funded employer groups, insurance carriers and regional and local provider networks that process end-user patient claims. FPN offers the utilization of its network to its more than 200 payor clients and members who, in turn, are able to capitalize on the discounted fee schedules FPN has negotiated with its healthcare providers. FPN contracts with physicians, hospitals, ancillary facilities, mid-level providers and other specialty healthcare providers who have the option of participating in one or more of our products (group health, workers compensation or auto liability).

    About SelectMDx for Prostate Cancer

    Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.

    About MDxHealth

    MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
  3. [verwijderd] 29 juni 2016 21:09
    quote:

    inspirator schreef op 4 mei 2015 22:33:

    MDXH should be worth at least 15.25 Euros a share compared to the current share price of 5 Euros a share and maybe much more over time. Biotech and smaller healthcare companies in Europe are often cheaper than their US equivalents.

    seekingalpha.com/article/3118556-mdxh...

    Morgen spin-off na publicatie Q1 cijfers MDxHealth en wederom publiciteit voor MDxHealth
    Er staat op hele korte termijn iets te gebeuren met MdxHealth.
  6. [verwijderd] 30 juni 2016 20:11
    quote:

    fly like an eagle schreef op 30 juni 2016 11:09:

    peebee ik denk dat het geen zin heeft om op inspirator en lordonhope e.d. te reageren, heb al voorgesteld aan Moderator dit soort vervuilers te verwijderen maar zonder succes.
    Inspirator vervuilt alleen de ondoorzichtige bedoelingen van shorters.

    Inspirator ziet de reeele waarde van MdxHealth
  7. peebee 1 juli 2016 08:56
    quote:

    inspirator schreef op 30 juni 2016 20:11:

    [...]

    Inspirator vervuilt alleen de ondoorzichtige bedoelingen van shorters.

    Inspirator ziet de reeele waarde van MdxHealth
    Ik zie ook een veel hogere waarde van MDXH...

    Maar je schreef dat er in hele korte tijd iets ging gebeuren betreffende MDXH...
    Ik ben gewoon benieuwd wat je bedoelt...that's all
    dus ben nog altijd benieuwd naar je reactie..
  9. Bahassie 6 juli 2016 08:26
    Totale netto shortpositie op 6 juli 2016: 0,00% (inclusief de laatst bekende positie van partijen die onder de meldingsgrens zijn gekomen).
    Bekende shortposities die onder de 0.5% vallen hebben geen meldingsplicht meer. Het is dus niet bekend of deze posities na de slotmelding nog bestaan en welke omvang ze hebben. In onderstaande grafiek worden ze toch weergegeven
    shortsell.nl/short/MDXHealth/90/archived

    Dit betekent dus ook dat GSA al lang de koers niet meer drukt met short gaan. Houdt uiteraard niet in dat ze wellicht andere spelletjes hebben gespeeld... maar goed. For what it's worth.
  11. [verwijderd] 12 juli 2016 20:38
    Reminder

    MDxHealth

    Voor technisch analisten geeft de grafiek van MDxHealth een klassiek koopsignaal. Het aandeel brak uit boven de vorige top van 19 maart 2014 van 5 euro. Beleggers zijn euforisch over de toekomst van MDxHealth. Het bedrijf, dat zich bezighoudt met de ontwikkeling en verkoop van diagnostische, prognostische en voorspellende kankertesten, maakt op 26 februari de cijfers bekend. Volgens forumleden zal er flink verlies worden geleden, maar gaat het vooral om de vooruitzichten. Beleggers vergelijken het aandeel met Galapagos en Crucell. Deze aandelen hebben recent een mooie rit naar boven gemaakt en ook MDxHealth kan volgens veel forumleden nog een flinke inhaalslag maken. Hoewel het koersdoel van KBC van 5,50 bijna is gehaald, zien de optimisten de koers nog veel verder oplopen.

    Het lijkt erop dat een partij de laatste dagen een groot belang aan het opbouwen is in MDxHealth. Op het drukbezochte forum van Eurobench vrezen beleggers dat er vandaag (23 februari) een bod wordt gedaan op MDxHealth door Exact Sciences. Meestal zijn beleggers blij met een overname, maar in dit geval vindt men de potentie van het aandeel groter dan het mogelijke overnamebod.

    “Maandag weten we het en ben benieuwd naar de koers van MDxHealth. Gaat Exact Sciences iets vertellen over MDXh? Gaan ze een bod uitbrengen op MDxH? Willen ze de samenwerking versterken of willen ze enkel Cologuard binnenhalen zodat zij voor 100% eigenaar worden? Aan het volume bij MDxH te zien de laatste dagen lijkt het er toch op dat er iets staat te gebeuren.”

    “Ik denk eerder dat Johnson&Johnson, Merck, Pfizer of GSK, de grote jongens dus, Mdx graag willen inlijven. Als je ziet wat Mdx nu al bereikt heeft en hoeveel ijzers er nog in het vuur liggen, dan is een overname volgens mij een kwestie van tijd. Hoop dat de koers dan wel boven de € 10 ligt.”

  14. [verwijderd] 14 juli 2016 23:58
    The fundamental drivers of MDXHealth share value are the expected sales of ConfirmMDX and the expected royalties on the sales of Cologuard. A conservative scenario analysis using a biotech valuation model based on net present values of future cash flows highlights a severe undervaluation of MDXHealth at the current market capitalization below EUR 150 million, even when considering discount rates in the order of 15-20%. MDXHealth share price is not consistent with Cologuard royalty prospects if the market adequately prices Exact Sciences. Under reasonable assumptions, the risk adjusted net present value of these future royalties easily exceeds the full market capitalisation of MDXHealth. Moreover, the share has the potential for an exponential price increase if ConfirmMDX sales pick up and if new markets are commercialized. Our realistic risk-adjusted net present value calculations indicate scope for two- to tenfold increase in MDXHealth share price, piggybacking on Exact Sciences' prospective commercial success reflected in its market valuation.
  15. [verwijderd] 15 juli 2016 00:07
    quote:

    inspirator schreef op 14 juli 2016 23:58:

    The fundamental drivers of MDXHealth share value are the expected sales of ConfirmMDX and the expected royalties on the sales of Cologuard. A conservative scenario analysis using a biotech valuation model based on net present values of future cash flows highlights a severe undervaluation of MDXHealth at the current market capitalization below EUR 150 million, even when considering discount rates in the order of 15-20%. MDXHealth share price is not consistent with Cologuard royalty prospects if the market adequately prices Exact Sciences. Under reasonable assumptions, the risk adjusted net present value of these future royalties easily exceeds the full market capitalisation of MDXHealth. Moreover, the share has the potential for an exponential price increase if ConfirmMDX sales pick up and if new markets are commercialized. Our realistic risk-adjusted net present value calculations indicate scope for two- to tenfold increase in MDXHealth share price, piggybacking on Exact Sciences' prospective commercial success reflected in its market valuation.
    Sounds good! Wanneer gaan we beginnen?
  16. forum rang 4 vreemdvermogen 15 juli 2016 00:19
    quote:

    inspirator schreef op 14 juli 2016 23:58:

    The fundamental drivers of MDXHealth share value are the expected sales of ConfirmMDX and the expected royalties on the sales of Cologuard. A conservative scenario analysis using a biotech valuation model based on net present values of future cash flows highlights a severe undervaluation of MDXHealth at the current market capitalization below EUR 150 million, even when considering discount rates in the order of 15-20%. MDXHealth share price is not consistent with Cologuard royalty prospects if the market adequately prices Exact Sciences. Under reasonable assumptions, the risk adjusted net present value of these future royalties easily exceeds the full market capitalisation of MDXHealth. Moreover, the share has the potential for an exponential price increase if ConfirmMDX sales pick up and if new markets are commercialized. Our realistic risk-adjusted net present value calculations indicate scope for two- to tenfold increase in MDXHealth share price, piggybacking on Exact Sciences' prospective commercial success reflected in its market valuation.
    Waarom kom je nu met een qoute van SNJbiostoxx ( een zeer onbetrouwbare toko)uit 2014?? Ik vind dit zeer misleidend.Gewoon bron vermelden. Je bent verkeerd bezig Inspirator.
  17. [verwijderd] 15 juli 2016 07:54
    quote:

    vreemd vermogen schreef op 15 juli 2016 00:19:

    [...]

    Waarom kom je nu met een qoute van SNJbiostoxx ( een zeer onbetrouwbare toko)uit 2014?? Ik vind dit zeer misleidend.Gewoon bron vermelden. Je bent verkeerd bezig Inspirator.
    het niet noemen van bron en/of datum publicatie is altijd een veeg teken d.w.z. VERDACHT. Sommigen denken dat ze slim zijn en anderen dom. Niet dus......
  18. [verwijderd] 15 juli 2016 08:35
    quote:

    inspirator schreef op 14 juli 2016 23:58:

    The fundamental drivers of MDXHealth share value are the expected sales of ConfirmMDX and the expected royalties on the sales of Cologuard. A conservative scenario analysis using a biotech valuation model based on net present values of future cash flows highlights a severe undervaluation of MDXHealth at the current market capitalization below EUR 150 million, even when considering discount rates in the order of 15-20%. MDXHealth share price is not consistent with Cologuard royalty prospects if the market adequately prices Exact Sciences. Under reasonable assumptions, the risk adjusted net present value of these future royalties easily exceeds the full market capitalisation of MDXHealth. Moreover, the share has the potential for an exponential price increase if ConfirmMDX sales pick up and if new markets are commercialized. Our realistic risk-adjusted net present value calculations indicate scope for two- to tenfold increase in MDXHealth share price, piggybacking on Exact Sciences' prospective commercial success reflected in its market valuation.
    Bron: Inspirator

    Ps onuitputtelijke bron
  19. [verwijderd] 16 juli 2016 09:07
    NCQA Proposes Inclusion of Cologuard in 2017 HEDIS Quality Measures - See more at: investor.exactsciences.com/investor-r...

    07/13/2016
    Updated HEDIS Measures Would Align with Final USPSTF Recommendations

    MADISON, Wis., July 13, 2016 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced that the National Committee for Quality Assurance (NCQA) has proposed to broaden the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening to include Cologuard® on a three-year schedule.

    Exact Sciences Corporation Logo
    "Inclusion in the HEDIS quality measures is an important milestone toward Cologuard becoming a standard of care for colon cancer screening," said Kevin Conroy, chairman and CEO of Exact Sciences. "Physicians, health systems and insurers would receive quality credit for using this patient-friendly screening option, which we believe will hasten its adoption."

    More than 90 percent of America's health plans measure quality based on HEDIS. Likewise, the CMS Star Ratings, which guides quality measures for Medicare Advantage plans, are directly impacted by HEDIS. The proposal to broaden the colorectal cancer screening measure is subject to a 30-day public comment period, which opened today. NCQA's effort would align HEDIS with the preeminent colorectal cancer screening recommendations, including those of the U.S. Preventive Services Task Force. The HEDIS 2017 quality measures will be used to audit the 2016 performance of physicians, health systems and insurers.

    "Primary care physicians and health plans are increasingly financially incentivized to demonstrate improvements in quality as measured by data, such as colon cancer screening rates," Mr. Conroy said. "Cologuard's inclusion in HEDIS is an important step toward helping them achieve better quality scores."

    About Cologuard
    The U.S. Preventive Services Task Force recently included Cologuard in its colorectal cancer screening recommendation statement, which resulted in NCQA's proposed mid-year update in order to align the HEDIS measures with the Task Force's recommendation statement. Cologuard is also the only colorectal cancer screening method that is supported by a built-in compliance service designed to actively encourage patients to complete their physician-ordered screening.

    Cologuard was approved by the FDA in August 2014 and results from Exact Sciences' prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society's (2014) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016). Stool DNA is included in the combined screening guidelines of the American Cancer Society/U.S. Multi-Society Task Force/American College of Radiology (2008) and the American College of Gastroenterology guidelines (2009). Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.

    - See more at: investor.exactsciences.com/investor-r...
1.073 Posts
Pagina: «« 1 ... 20 21 22 23 24 ... 54 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!